RXRX:NASDAQRecursion Pharmaceuticals, Inc. Analysis

Recursion Pharmaceuticals is trading below its 20‑day (≈$3.25) and 50‑day (≈$3.30) simple moving averages, with a bearish MACD crossover and an RSI hovering around 38, indicating lingering downside momentum but no extreme oversold condition. The stock sits just above a calculated support level of $2.77 and faces resistance near $3.71, while volume has been trending upward, suggesting that any break of support could accelerate a decline. Recent earnings showed a revenue miss ($6.47 M vs. $15.78 M consensus) but a narrower loss per share (‑$0.22 vs. ‑$0.30 expected), highlighting a mixed short‑term narrative. Fundamentally, the company is cash‑rich ($654 M) yet burdened by a debt‑to‑equity ratio above 7, negative operating cash flow, and a steep 30‑day volatility of over 54% coupled with a beta near 3, underscoring high systematic risk.
Despite these headwinds, analysts collectively rate the stock as a "buy" with a median price target of $6.00, implying more than 100% upside, and the pipeline of AI‑driven drug candidates (e.g., REC‑4881, REC‑617) offers a long‑term growth catalyst. The valuation appears mixed: a price‑to‑book of 1.5 is reasonable, but a price‑to‑sales of 23.7 signals premium pricing relative to current sales. With no dividend and a sector classified as high‑risk biotech, investors should weigh the potential upside against the pronounced volatility and regulatory uncertainty.